- Home
- IIIV vs AVXL Comparison
IIIV vs AVXL Comparison
Compare IIIV & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- AVXL
- Stock Information
- Founded
- IIIV 2012
- AVXL 2004
- Country
- IIIV United States
- AVXL United States
- Employees
- IIIV N/A
- AVXL N/A
- Industry
- IIIV EDP Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IIIV Technology
- AVXL Health Care
- Exchange
- IIIV Nasdaq
- AVXL Nasdaq
- Market Cap
- IIIV 707.2M
- AVXL 794.0M
- IPO Year
- IIIV 2018
- AVXL N/A
- Fundamental
- Price
- IIIV $28.63
- AVXL $10.82
- Analyst Decision
- IIIV Buy
- AVXL Strong Buy
- Analyst Count
- IIIV 7
- AVXL 2
- Target Price
- IIIV $29.57
- AVXL $44.00
- AVG Volume (30 Days)
- IIIV 325.4K
- AVXL 1.2M
- Earning Date
- IIIV 08-07-2025
- AVXL 08-15-2025
- Dividend Yield
- IIIV N/A
- AVXL N/A
- EPS Growth
- IIIV 4907.14
- AVXL N/A
- EPS
- IIIV 4.75
- AVXL N/A
- Revenue
- IIIV $241,651,000.00
- AVXL N/A
- Revenue This Year
- IIIV N/A
- AVXL N/A
- Revenue Next Year
- IIIV $5.07
- AVXL N/A
- P/E Ratio
- IIIV $8.44
- AVXL N/A
- Revenue Growth
- IIIV 5.59
- AVXL N/A
- 52 Week Low
- IIIV $20.42
- AVXL $4.93
- 52 Week High
- IIIV $30.10
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- IIIV 51.52
- AVXL 49.42
- Support Level
- IIIV $27.70
- AVXL $10.60
- Resistance Level
- IIIV $28.50
- AVXL $12.68
- Average True Range (ATR)
- IIIV 0.73
- AVXL 0.84
- MACD
- IIIV -0.21
- AVXL -0.18
- Stochastic Oscillator
- IIIV 22.95
- AVXL 6.49
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.